Palbociclib Pfizer

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Palbociclib 75mg

Available from:

Pfizer New Zealand Limited

Dosage:

75 mg

Pharmaceutical form:

Film coated tablet

Composition:

Active: Palbociclib 75mg Excipient: Colloidal silicon dioxide Crospovidone Opadry purple 03K100008 Magnesium stearate Microcrystalline cellulose Succinic acid

Prescription type:

Prescription

Therapeutic indications:

PALBOCICLIB PFIZER is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: · in combination with an aromatase inhibitor; · in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.

Product summary:

Package - Contents - Shelf Life: Blister pack, PVC/OPA/AI/PVC foil with aluminium foil lidding - 21 tablets - 36 months from date of manufacture stored at or below 30°C protect from moisture

Authorization date:

2022-03-30